Immunotherapy plus chemotherapy before surgery for early-stage lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with non-small cell lung cancer that is stage II, IIIA, or certain stage IIIB cases, and is considered surgically removable (resectable).
- You have not received any previous cancer treatment such as chemotherapy, radiation, or surgery for this disease.
- You do not have certain genetic changes (EGFR or ALK) that have approved targeted therapies available.
- You are generally well enough to carry out daily activities (performance status 0 or 1).
- You can provide a tumor tissue sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
This trial tests whether combining two drugs, adebrelimab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that blocks blood supply to tumors), before surgery can improve outcomes for people with early-stage non-small cell lung cancer. The goal is to shrink the tumor and make surgery more effective.
This study tests whether combining chemotherapy with immunotherapy before and after chemoradiation helps people with stage III lung cancer that can be removed by surgery. It might improve how well treatment works and reduce the chance of cancer coming back.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests whether giving a combination of an immunotherapy drug (adebrelimab) and chemotherapy before surgery can shrink tumors better in lung cancer that has certain genetic changes. The hope is that this pre-surgery treatment will improve outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.